thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » COVAXIN Publishes Highest Number of Covid-19 Vaccines Research Studies

Latest News

COVAXIN Publishes Highest Number of Covid-19 Vaccines Research Studies

TheNewsFacts
Last updated: August 5, 2021 11:20 am
TheNewsFacts
Share
COVAXIN Publishes Highest Number of Covid-19 Vaccines Research Studies
SHARE

COVAXIN India’s indigenously developed and manufactured COVID-19 Vaccine continues to demonstrate its scientific commitment by sharing and publishing data generation and data transparency. So far, Bharat Biotech has published full data of all research studies of its COVAXIN®, India’s first indigenous COVID-19 vaccine in 10 globally recognized scientific journals.

In a timely approach to peer review, the company has already published as many as Ten research studies on the safety and efficacy of COVAXIN® in five globally reputed peer-reviewed journals in a span of just twelve months.

COVAXIN®, a whole-virion inactivated coronavirus vaccine, has many firsts to its credit in data transparency. It is the first and only product to have published any data from human clinical trials in India. It is the only product to have any data on emerging variants. It is also the first and only COVID-19 vaccine to have efficacy data in Indian populations.

COVAXIN data published in 10 leading scientific publications – a first amongst peers

Image Courtesy Bharat Biotech – Covaxin trial studies in 10 publications

In vaccine development, preclinical studies involve the testing of vaccine candidates in laboratory animals. Bharat Biotech completed three preclinical studies, which are published in Cellpress, a peer-reviewed journal. The studies on COVAXIN’s Phase I (done to assess a vaccine’s safety, immune response and to determine the right dosage), and Phase II clinical trial (carried out to assess the safety and the ability of the vaccine to generate an immune response) are published by the peer-reviewed journal, The Lancet – Infectious Diseases.

The full data from studies on COVAXIN’s neutralization of variants are already published at the peer-reviewed journals of bioRxiv, Clinical Infectious Diseases, and Journal of Travel Medicine.

The study on the neutralization of Beta and Delta variants (B.1.351 and B.1.617.2 respectively) is published at bioRxiv, and the study on B1.1.28 variant, at Journal of Travel Medicine, while the studies on B.1.617 variant and Alpha variant (B.1.1.7) are published at Clinical Infectious Disease, and Journal of Travel Medicine respectively.

The published studies are widely cited for the rigor and breadth that Bharat Biotech brings to its clinical trials. Currently, data from both efficacy and safety follow-up of COVAXIN’s Phase III trial is being analyzed and compiled. Upholding its uncompromising commitment to integrity, the company will make Phase III trials data from the final analysis public in July 2021.

Today, COVAXIN also received Hungarian GMP certification for its manufacturing practices.

TAGGED: Bharat Biotech, Covaxin, covid vaccines, COVID19 Vaccines, Science, Vaccinas
Share This Article
Twitter Email Copy Link Print
Previous Article Olympics 2020: Historic Bronze Medal for India 41 years after Olympics 2020: Historic Bronze Medal for India 41 years after
Next Article Watch the Video - PM Modi Call to Indian Hockey Captain in Tokyo 2020 Watch the Video – PM Modi Call to Indian Hockey Captain in Tokyo 2020

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

Mason Mount Joins Man United in Blockbuster £60 Mn Deal

Mason Mount has officially joined the ranks of Manchester United in a sensational deal worth…

By TheNewsFacts

New Chinese Glass Invention is as Hard as Diamond

Chinese scientists probably have in hand a new invention, a glass material which according to…

By TheNewsFacts

Vedanta Share Price is the Sensex Show Stopper this Week

Vedanta share price soared nearly 3% on Tuesday morning to hit a fresh 52-week high…

By TheNewsFacts

You Might Also Like

Bhool Chuk Maaf Box Office Report
Latest News

Bhool Chuk Maaf Crosses ₹54 Cr Globally in 7 Days

By NewsFacts Bureau
Bharat Biotech HILLCHOL
Latest News

Bharat Biotech’s Oral Cholera Vaccine HILLCHOL Demonstrates Success in Phase III Clinical Studies

By TheNewsFacts
Biovet Lumpy Skin Disease Vaccine Launched
Latest News

BIOLUMPIVAXIN: New Vaccine Now Available to Protect Livestock from LSD

By NewsFacts Bureau
Google AI First Accelerator 2025 India
Latest News

Google Opens 2025 India AI First Accelerator: $17B Opportunity for Startups

By NewsFacts Bureau
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?